Pub Date : 2024-03-14DOI: 10.20517/2394-5079.2024.24
Z. Meng
{"title":"Chinese expert consensus on composite ablation system for the treatment of primary liver cancer (2023 edition)","authors":"Z. Meng","doi":"10.20517/2394-5079.2024.24","DOIUrl":"https://doi.org/10.20517/2394-5079.2024.24","url":null,"abstract":"","PeriodicalId":12959,"journal":{"name":"Hepatoma Research","volume":"3 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140242819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-03-12DOI: 10.20517/2394-5079.2024.33
Jizhou Wang, Lianxin Liu
{"title":"Introduction of Chinese expert consensus on neoadjuvant therapy for primary liver cancer (2023 edition)","authors":"Jizhou Wang, Lianxin Liu","doi":"10.20517/2394-5079.2024.33","DOIUrl":"https://doi.org/10.20517/2394-5079.2024.33","url":null,"abstract":"","PeriodicalId":12959,"journal":{"name":"Hepatoma Research","volume":"57 12","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140248464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-02-23DOI: 10.20517/2394-5079.2024.13
Alessandro D. Mazzotta, Desirée Bonci
{"title":"Advancements in hepatocellular carcinoma diagnosis and treatment: liquid biopsy and surgical as precision treatment","authors":"Alessandro D. Mazzotta, Desirée Bonci","doi":"10.20517/2394-5079.2024.13","DOIUrl":"https://doi.org/10.20517/2394-5079.2024.13","url":null,"abstract":"","PeriodicalId":12959,"journal":{"name":"Hepatoma Research","volume":"194 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140437773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-24DOI: 10.20517/2394-5079.2024.02
Haibin Zhang
{"title":"Introduction of the Chinese expert consensus on postoperative adjuvant therapy for hepatocellular carcinoma (2023 Edition)","authors":"Haibin Zhang","doi":"10.20517/2394-5079.2024.02","DOIUrl":"https://doi.org/10.20517/2394-5079.2024.02","url":null,"abstract":"","PeriodicalId":12959,"journal":{"name":"Hepatoma Research","volume":"51 18","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139600910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-18DOI: 10.20517/2394-5079.2023.114
A. Díaz, Samantha M Ruff, T. Pawlik
Hepatocellular carcinoma (HCC) poses a significant public health challenge within the US, exerting an increasingly substantial influence on cancer-related deaths. However, the HCC burden is not uniformly distributed, with significant disparities related to race, ethnicity, and socioeconomic status. This manuscript comprehensively reviews the multifaceted origins of HCC disparities, exploring their roots in the sociocultural environment, socioeconomics, the physical/built environment, and the healthcare/political systems. The sociocultural environment highlights the unique challenges faced by racial and ethnic minority populations, including language barriers, cultural beliefs, and limited healthcare access. The socioeconomics and the physical/built environment section emphasize the impact of neighborhood poverty, geographic disparities, and healthcare infrastructure on HCC outcomes. The healthcare and political systems play a pivotal role in driving HCC disparities through practice guidelines, healthcare policies, insurance coverage, and access to care. Inconsistent practice guidelines across specialties and variations in insurance coverage contribute to disparities in HCC surveillance and treatment. In conclusion, addressing HCC disparities requires a multifaceted, patient-centered approach that includes cultural competence, infrastructure enhancements, policy changes, and improved access to care. Collaborative efforts among healthcare professionals, researchers, policymakers, and institutions are essential to reducing the burden of HCC on marginalized communities and ensuring equitable care for all individuals affected by this complex disease.
{"title":"Racial, ethnic, and socioeconomic differences in hepatocellular carcinoma across the United States","authors":"A. Díaz, Samantha M Ruff, T. Pawlik","doi":"10.20517/2394-5079.2023.114","DOIUrl":"https://doi.org/10.20517/2394-5079.2023.114","url":null,"abstract":"Hepatocellular carcinoma (HCC) poses a significant public health challenge within the US, exerting an increasingly substantial influence on cancer-related deaths. However, the HCC burden is not uniformly distributed, with significant disparities related to race, ethnicity, and socioeconomic status. This manuscript comprehensively reviews the multifaceted origins of HCC disparities, exploring their roots in the sociocultural environment, socioeconomics, the physical/built environment, and the healthcare/political systems. The sociocultural environment highlights the unique challenges faced by racial and ethnic minority populations, including language barriers, cultural beliefs, and limited healthcare access. The socioeconomics and the physical/built environment section emphasize the impact of neighborhood poverty, geographic disparities, and healthcare infrastructure on HCC outcomes. The healthcare and political systems play a pivotal role in driving HCC disparities through practice guidelines, healthcare policies, insurance coverage, and access to care. Inconsistent practice guidelines across specialties and variations in insurance coverage contribute to disparities in HCC surveillance and treatment. In conclusion, addressing HCC disparities requires a multifaceted, patient-centered approach that includes cultural competence, infrastructure enhancements, policy changes, and improved access to care. Collaborative efforts among healthcare professionals, researchers, policymakers, and institutions are essential to reducing the burden of HCC on marginalized communities and ensuring equitable care for all individuals affected by this complex disease.","PeriodicalId":12959,"journal":{"name":"Hepatoma Research","volume":"3 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139526054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Intrahepatic cholangiocarcinoma (ICC), a rare but rising global malignancy originating from the bile ducts, poses significant challenges in terms of effective treatment and patient outcomes. While surgical excision remains the curative option, its limited efficacy necessitates more therapeutic strategies, including systemic therapies. The management of ICC involves a multidisciplinary approach, with treatment decisions guided by patient-specific and tumor-specific factors. Gemcitabine-cisplatin (GEMCIS) chemotherapy has been a standard first-line therapy, but recent advancements in immunotherapy, particularly the introduction of durvalumab, have provided new hope. Additionally, gene mutation-based therapies, targeting fibroblast growth factor receptors (FGFRs), isocitrate dehydrogenase-1 (IDH1), human epidermal growth factor receptor-2 (HER2), and B-RAF proto-oncogene (BRAF), offer promising prospects for personalized treatment. High-throughput genomic profiling technologies have facilitated the identification of actionable targets and the development of innovative therapeutic approaches. This review summarizes the mutation-based therapies in ICC, including FDA-approved targeted drugs and ongoing clinical trials, highlighting the evolving landscape of ICC treatment.
肝内胆管癌（ICC）是一种源自胆管的罕见恶性肿瘤，但在全球呈上升趋势，给有效治疗和患者预后带来了巨大挑战。虽然手术切除仍是治愈的选择，但其有限的疗效需要更多的治疗策略，包括全身疗法。ICC 的治疗涉及多学科方法，治疗决策以患者特异性和肿瘤特异性因素为指导。吉西他滨-顺铂（GEMCIS）化疗一直是标准的一线疗法，但免疫疗法的最新进展，尤其是durvalumab的问世，给人们带来了新的希望。此外，针对成纤维细胞生长因子受体（FGFR）、异柠檬酸脱氢酶-1（IDH1）、人表皮生长因子受体-2（HER2）和B-RAF原癌基因（BRAF）的基因突变疗法也为个性化治疗带来了希望。高通量基因组剖析技术促进了可操作靶点的确定和创新治疗方法的开发。本综述总结了基于基因突变的 ICC 治疗方法，包括美国 FDA 批准的靶向药物和正在进行的临床试验，重点介绍了不断发展的 ICC 治疗方法。
{"title":"Mutation-based therapies for intrahepatic cholangiocarcinoma: new options on the horizon","authors":"Si-yuan Pan, Yu-Hang Ye, Zheng-jun Zhou, Jia Fan, Jian Zhou, Shaolai Zhou","doi":"10.20517/2394-5079.2023.44","DOIUrl":"https://doi.org/10.20517/2394-5079.2023.44","url":null,"abstract":"Intrahepatic cholangiocarcinoma (ICC), a rare but rising global malignancy originating from the bile ducts, poses significant challenges in terms of effective treatment and patient outcomes. While surgical excision remains the curative option, its limited efficacy necessitates more therapeutic strategies, including systemic therapies. The management of ICC involves a multidisciplinary approach, with treatment decisions guided by patient-specific and tumor-specific factors. Gemcitabine-cisplatin (GEMCIS) chemotherapy has been a standard first-line therapy, but recent advancements in immunotherapy, particularly the introduction of durvalumab, have provided new hope. Additionally, gene mutation-based therapies, targeting fibroblast growth factor receptors (FGFRs), isocitrate dehydrogenase-1 (IDH1), human epidermal growth factor receptor-2 (HER2), and B-RAF proto-oncogene (BRAF), offer promising prospects for personalized treatment. High-throughput genomic profiling technologies have facilitated the identification of actionable targets and the development of innovative therapeutic approaches. This review summarizes the mutation-based therapies in ICC, including FDA-approved targeted drugs and ongoing clinical trials, highlighting the evolving landscape of ICC treatment.","PeriodicalId":12959,"journal":{"name":"Hepatoma Research","volume":"21 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139532443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-09DOI: 10.20517/2394-5079.2023.69
Mirko Minini, Allan Pavy, Bouchra Lekbaby, L. Fouassier
Cholangiocarcinoma (CCA) is a highly aggressive tumor of the biliary tree characterized by an intense desmoplastic tumor microenvironment (TME). To date, treatment of CCA remains challenging; tumor resection is the only curative treatment with a high recurrence probability. Besides resection, therapeutic options have moved forward with the advent of immunotherapies, but these remain limited and low effective. Our knowledge about the cellular interplays in CCA is still fragmentary. An area is currently emerging regarding the potential role of cancer cell plasticity in the genesis of an immunosuppressive microenvironment. The cancer cells’ ability to acquire stemness properties and to disseminate through an epithelial-mesenchymal transition (EMT) shape a tumor immune microenvironment that supports cancer progression by attracting immunosuppressive cells including myeloid-derived suppressor cells (MDSCs), regulatory T cells (Tregs), M2 macrophages, and by increasing the expression of inhibitory immune checkpoints such as PD-1/PD-L-1. EMT-inducing transcription factors (EMT-TF) have recently emerged as regulators of tumor immunity by creating an immunosuppressive microenvironment. This review delves into the molecular mechanisms underlying the existing links between EMT/stemness and tumor immune microenvironment, as well as the last discoveries in CCA.
胆管癌（Colangiocarcinoma，CCA）是胆道树上一种侵袭性极强的肿瘤，其特点是肿瘤微环境（TME）具有强烈的去肿瘤性。迄今为止，CCA 的治疗仍然充满挑战；肿瘤切除是唯一的根治性治疗方法，但复发几率很高。除切除术外，免疫疗法的出现也推动了治疗方案的发展，但这些方案仍然有限且疗效不佳。我们对 CCA 中细胞相互作用的了解还很零碎。癌细胞的可塑性在形成免疫抑制微环境中的潜在作用是目前正在出现的一个领域。癌细胞有能力获得干性特性，并通过上皮-间质转化（EMT）进行扩散，形成肿瘤免疫微环境，通过吸引免疫抑制细胞（包括髓源性抑制细胞（MDSCs）、调节性T细胞（Tregs）、M2巨噬细胞），以及增加抑制性免疫检查点（如PD-1/PD-L-1）的表达，支持癌症进展。最近，EMT诱导转录因子（EMT-TF）通过创造免疫抑制微环境成为肿瘤免疫的调节因子。本综述将深入探讨 EMT/干性与肿瘤免疫微环境之间现有联系的分子机制，以及在 CCA 中的最新发现。
{"title":"Crosstalk between cancer cell plasticity and immune microenvironment in cholangiocarcinoma","authors":"Mirko Minini, Allan Pavy, Bouchra Lekbaby, L. Fouassier","doi":"10.20517/2394-5079.2023.69","DOIUrl":"https://doi.org/10.20517/2394-5079.2023.69","url":null,"abstract":"Cholangiocarcinoma (CCA) is a highly aggressive tumor of the biliary tree characterized by an intense desmoplastic tumor microenvironment (TME). To date, treatment of CCA remains challenging; tumor resection is the only curative treatment with a high recurrence probability. Besides resection, therapeutic options have moved forward with the advent of immunotherapies, but these remain limited and low effective. Our knowledge about the cellular interplays in CCA is still fragmentary. An area is currently emerging regarding the potential role of cancer cell plasticity in the genesis of an immunosuppressive microenvironment. The cancer cells’ ability to acquire stemness properties and to disseminate through an epithelial-mesenchymal transition (EMT) shape a tumor immune microenvironment that supports cancer progression by attracting immunosuppressive cells including myeloid-derived suppressor cells (MDSCs), regulatory T cells (Tregs), M2 macrophages, and by increasing the expression of inhibitory immune checkpoints such as PD-1/PD-L-1. EMT-inducing transcription factors (EMT-TF) have recently emerged as regulators of tumor immunity by creating an immunosuppressive microenvironment. This review delves into the molecular mechanisms underlying the existing links between EMT/stemness and tumor immune microenvironment, as well as the last discoveries in CCA.","PeriodicalId":12959,"journal":{"name":"Hepatoma Research","volume":"32 14","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139442818","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-01DOI: 10.20517/2394-5079.2023.73
Jing-Yu Tan, Zhuo-Ying Li, Q. Shen, Yan Zhang, J. Tuo, Da-ke Liu, Y. Tan, Honglan Li, Yong-Bing Xiang
Aims : Epidemiological evidence has revealed varying degrees of relationship between physical activity and risk of most cancers, but the association between physical activity and risk for primary liver cancer in Chinese has seldom been reported. This study aims to characterize the associations between different physical activity types and liver cancer risk in Chinese women. Methods: We collected physical activity information through the physical activity questionnaire (PAQ) and assigned a corresponding metabolic equivalent value according to the physical activity compendium. Multivariable-adjusted Cox regression models were utilized to estimate the hazard ratios (HRs) and 95% confidence intervals (CIs) for the relationships between physical activity and liver cancer. Results : A total of 72,674 females were enrolled in the cohort, with a median follow-up time of 18.12 years. By the end of 2016, 255 females were identified as incident cases of liver cancer. In Multivariable-adjusted Cox regression analysis, total physical activity (TPA), daily living physical activity (DPA) and leisure-time physical activity (LTPA) were not associated with the liver cancer risk in women. The highest tertile vs . none of HRs (95%CIs) were 0.82 (0.58, 1.17) for TPA, 0.80 (0.56, 1.15) for DPA, and 1.15 (0.82, 1.61) for adult LTPA in terms of measures as the METs-hour/week. For each activity, we found that the HRs (95%CIs) were 0.77 (0.55, 1.08) for stair climbing and 0.78 (0.53, 1.15) for participation in housework after further adjusting for body mass index and type 2 diabetes. Conclusion : Null significant results were found in the association between physical activity and female liver cancer risk in China.
{"title":"Associations between physical activity and risk of liver cancer: results from a population-based cohort study in Chinese women","authors":"Jing-Yu Tan, Zhuo-Ying Li, Q. Shen, Yan Zhang, J. Tuo, Da-ke Liu, Y. Tan, Honglan Li, Yong-Bing Xiang","doi":"10.20517/2394-5079.2023.73","DOIUrl":"https://doi.org/10.20517/2394-5079.2023.73","url":null,"abstract":"Aims : Epidemiological evidence has revealed varying degrees of relationship between physical activity and risk of most cancers, but the association between physical activity and risk for primary liver cancer in Chinese has seldom been reported. This study aims to characterize the associations between different physical activity types and liver cancer risk in Chinese women. Methods: We collected physical activity information through the physical activity questionnaire (PAQ) and assigned a corresponding metabolic equivalent value according to the physical activity compendium. Multivariable-adjusted Cox regression models were utilized to estimate the hazard ratios (HRs) and 95% confidence intervals (CIs) for the relationships between physical activity and liver cancer. Results : A total of 72,674 females were enrolled in the cohort, with a median follow-up time of 18.12 years. By the end of 2016, 255 females were identified as incident cases of liver cancer. In Multivariable-adjusted Cox regression analysis, total physical activity (TPA), daily living physical activity (DPA) and leisure-time physical activity (LTPA) were not associated with the liver cancer risk in women. The highest tertile vs . none of HRs (95%CIs) were 0.82 (0.58, 1.17) for TPA, 0.80 (0.56, 1.15) for DPA, and 1.15 (0.82, 1.61) for adult LTPA in terms of measures as the METs-hour/week. For each activity, we found that the HRs (95%CIs) were 0.77 (0.55, 1.08) for stair climbing and 0.78 (0.53, 1.15) for participation in housework after further adjusting for body mass index and type 2 diabetes. Conclusion : Null significant results were found in the association between physical activity and female liver cancer risk in China.","PeriodicalId":12959,"journal":{"name":"Hepatoma Research","volume":"17 12","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139125970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：